Home › Funds › Defilade Capital Management, L.P. › PTCT

Defilade Capital Management, L.P. position in PTCT

PTC THERAPEUTICS INC · Health Care

Defilade Capital Management, L.P. reported holding 433,699 shares of PTCT (PTC THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$35.4M, representing 4.74% of its reported portfolio and ranking #5 among its reported holdings. Defilade Capital Management, L.P. has disclosed PTCT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)433.70K sh
Reported value held$35.38M
Portfolio Weight4.74%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Defilade Capital Management, L.P.'s PTCT position evolved

Defilade Capital Management, L.P. first disclosed a stake in PTCT in Q1 2026 at 376,165 shares (US$25.6M). The position peaked in Q2 2026 at 433,699 shares, worth US$35.4M. Across 2 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 433,699 shares valued at US$35.4M — an increase of 57,534 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 376.17K $25.63M New
Q2 2026 433.70K $35.38M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTCT and 13F data

PTCT (PTC THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in PTCT — the largest reported positions include RTW INVESTMENTS, LP (US$631.9M), TORONTO DOMINION BANK (US$176.7M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$159.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTCT

All PTCT fund holders →

FAQ

How long has Defilade Capital Management, L.P. held PTCT?

Defilade Capital Management, L.P. has disclosed PTCT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Defilade Capital Management, L.P.'s current position in PTCT?

As of Q2 2026, Defilade Capital Management, L.P. holds 433.70K shares of PTCT (PTC THERAPEUTICS INC), valued at $35.38M, representing 4.74% of its reported portfolio and ranking #5.

Has Defilade Capital Management, L.P. been buying or selling PTCT?

In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. increased its position in PTCT. The position peaked in Q2 2026 at 433.70K shares.

Which other funds hold PTCT?

Other major institutional holders of PTCT include RTW INVESTMENTS, LP, TORONTO DOMINION BANK, WESTFIELD CAPITAL MANAGEMENT CO LP, among 54 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.